<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) present with <z:hpo ids='HP_0001903'>anemia</z:hpo> and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IOL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is rather limited </plain></SENT>
<SENT sid="2" pm="."><plain>Here we present the results of a multi-center trial evaluating the efficacy and safety of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> (DFX) in low and intermediate-1 risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with transfusion-dependent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IOL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients with transfusion frequency of &gt; 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden <z:chebi fb="0" ids="49005">deferasirox</z:chebi> was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only </plain></SENT>
<SENT sid="4" pm="."><plain>LIC was measured by MRI at baseline and end of study using the method by St </plain></SENT>
<SENT sid="5" pm="."><plain>Pierre et al </plain></SENT>
<SENT sid="6" pm="."><plain>The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days </plain></SENT>
<SENT sid="7" pm="."><plain>Mean daily dose of DFX was 19 mg/kg/day </plain></SENT>
<SENT sid="8" pm="."><plain>Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>In 7 (13��%) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy </plain></SENT>
<SENT sid="10" pm="."><plain>For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>Of <z:hpo ids='HP_0000001'>all</z:hpo> patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively </plain></SENT>
<SENT sid="12" pm="."><plain>The most common adverse events (≥ 10 % of <z:hpo ids='HP_0000001'>all</z:hpo> patients) with suspected drug relationship were <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (n = 25, 46 %), <z:hpo ids='HP_0002018'>nausea</z:hpo> (n = 13, 24 %), upper <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> (n = 8, 15 %), serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> increase (n = 16, 30 %) and <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> (n = 5, 9 %) </plain></SENT>
<SENT sid="13" pm="."><plain>Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %) </plain></SENT>
<SENT sid="14" pm="."><plain>Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %) </plain></SENT>
<SENT sid="15" pm="."><plain>Initiation of treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IOL</z:e> with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI </plain></SENT>
<SENT sid="16" pm="."><plain>The safety profile of DFX was comparable to previous observations </plain></SENT>
</text></document>